Share on LinkedInShare on LinkedIn

ARTICLE · 16 JULY 2019

Pre-Amended PMNOC Regulations: Court Decisions On The Merits (Polymorph, Salt, Formulation Patents)

There have been two Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) decisions on the merits so far in 2019 and a pair of appeal decisions

CanadaIntellectual Property

There have been two Patented Medicines (Notice of Compliance) Regulations  (PMNOC Regulations) decisions on the merits so far in 2019 and a pair of appeal decisions: (i) Pfizer was successful in Apotex and Teva’s appeals regarding the validity of a patent claiming Form I o-desmethyl-venlafaxine (ODV)  succinate  (Pfizer’s PRISTIQ); (ii) Valeant was successful against Generic Partners Canada, which alleged invalidity of Valeant’s patent for a controlled-release dosage form of metformin  (Valeant’s GLUMETZA); and (iii) Apotex was successful in its obviousness and claim overbreadth allegations relating to Servier’s patent claiming the arginine salt of perindopril and its hydrates in connection with Apotex’s perindopril arginine/amlodipine product (Servier’s VIACORAM).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

See more popular content from